|8th September 2020||Anthony Waclawski||35,000||Grant/award etc.||$0.00|
|26th July 2020||Chaim Lebovits||31,185||Grant/award etc.||$0.00|
|16th July 2020||David Setboun||5,000||Open or private purchase||$12.95||$64,740.00|
|16th July 2020||International Holdings Ltd. Acc||7,823||Open or private sale||$13.47||$105,350.78|
|15th July 2020||International Holdings Ltd. Acc||18,430||Open or private sale||$13.12||$241,714.98|
|15th July 2020||Sankesh Abbhi||46,779||Open or private purchase||$12.99||$607,659.21|
|13th July 2020||International Holdings Ltd. Acc||40,000||Open or private sale||$13.52||$540,952.00|
|10th July 2020||International Holdings Ltd. Acc||2,000||Open or private sale||$13.35||$26,700.00|
|9th July 2020||International Holdings Ltd. Acc||3,500||Open or private sale||$13.13||$45,938.55|
|2nd July 2020||Anthony J. Polverino||488||Grant/award etc.||$30.66||$14,962.08|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Brainstorm Cell Therapeutics, Inc. was founded on September 22, 2000 and is headquartered in New York, NJ. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells.